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Abstract—The reference standards halo-GSK1482160 (F-, Br-, and I-) and their corresponding precursors desmethyl-halo-GSK1482160 
(F-, Br-, and I-) were synthesized from (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid or (S)-5-oxopyrrolidine-2-carboxylic acid and 2-
halo-3-(trifluoromethyl)benzylamine (F-, Br-, and I-) in one step with 45-93% yields. The target tracers [11C]halo-GSK1482160 (F-, Br-, 
and I-) were prepared from desmethyl-halo-GSK1482160 (F-, Br-, and I-) with [11C]CH3OTf under basic conditions (NaOH-Na2CO3,
solid, w/w 1:2) through N-[11C]methylation and isolated by HPLC combined with SPE in 40-50% decay corrected radiochemical yield. 
The radiochemical purity was >99%, and the molar activity (AM) at end of bombardment (EOB) was 370-740 GBq/mol. The potency of 
halo-GSK1482160 (F-, Br-, and I-) in comparison with GSK1482160 (Cl-) was determined by a radioligand competitive binding assay 
using [11C]GSK1482160, and the binding affinity Ki values for halo-GSK1482160 (F-, Br-, and I-) and GSK1482160 (Cl-) are 54.2, 2.5,
1.9 and 3.1 nM, respectively.   
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The purinergic receptor P2X ligand-gated ion channel 
type 7 (P2X7R) is an adenosine triphosphate (ATP)-
gated ion-channel, and P2X7R is a key player in 
inflammation.
1
 P2X7R is an emerging therapeutic target
in central nervous system (CNS) diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease 
(PD), because the overexpression of P2X7R is closely 
associated with neuroinflammation.
2
 P2X7R has
become a novel molecular imaging target for 
neuroinflammation via biomedical imaging technique 
positron emission tomography (PET).
3
 Recently several
radioligands targeting P2X7R have been developed and 
evaluated in animals and human, and the representative 
radioligands are shown in Figure 1.
4-15
 However,
biological evaluation indicated some of these P2X7R 
radioligands have significant drawbacks like not potent 
enough binding affinity Ki values, short half-life of 
radionuclide carbon-11 (t1/2, 20.4 min), limited blood-
brain barrier (BBB) penetration and/or little brain 
uptake. Thus an ideal P2X7R radioligand that can be 
used in the clinical setting to study P2X7R expression 
levels in neurodegenerative disorders remains to be 
discovered. In our previous work, we have developed 
and characterized [
11
C]GSK1482160 as a P2X7R
radioligand for neuroinflammation,
7,8
 clinical evaluation
of [
11
C]GSK1482160 in healthy controls and patients is
currently underway, the estimation of radiation 
dosimetry for [
11
C]GSK1482160 in normal human
subjects has been reported, and the results indicated 
brain uptake was low, but in most other organs the 
uptake and clearance of [
11
C]GSK1482160 appears
suitable for use in PET assessment of P2X7R 
expression as a potential marker of regional 
inflammation.
15
 In addition, a series of [
18
F]fluoroalkyl
derivatives of GSK1482160 like [
18
F]fluoroethyl
derivative [
18
F]IUR-1601 and [
18
F]fluoropropyl
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derivative [
18
F]IUR-1602 have been also developed in 
this laboratory.
12,13
 Although these two fluorine-18 
radioligands has a longer half-life (t1/2, 109.7 min) and 
greater potential for widespread clinical use, they 
requires complicated two-step radiosynthetic procedures 
and are unstable under predisposing radiosynthetic 
conditions for an elimination reaction, resulting low 
radiochemical yield.
12,13
 To overcome the problems 
with [
11
C]GSK1482160 (short half-life and low brain 
uptake) and with [
18
F]IUR-1601 as well as [
18
F]IUR-
1602 (complex radiosynthesis and short-term stability), 
in this ongoing study, we initially proposed to develop 
[
18
F]GSK1482160, in which GSK1482160 and its 
bromine and iodide analogs serve as the labeling 
precursors for [
18
F]GSK1482160, but the in vitro 
biological evaluation results of halo-GSK1482160 (F-, 
Cl-, Br-, and I-) analogs suggest [
18
F]GSK1482160 is 
not a useful radioligand, instead [
11
C]Br-GSK1482160 
and [
11
C]I-GSK1482160 could be useful radioligands. 
Therefore, we turned our effort to develop [
11
C]halo-
GSK1482160 (F-, Br-, and I-) analogs. Herein, we 
report the design, synthesis, radiolabeling and initial in 
vitro biological evaluation of new P2X7R radioligands 
[
11
C]halo-GSK1482160 (F-, Br-, and I-) analogs 
(Figure 1).   
 
Figure 1. Radioligands for imaging of P2X7R.  
 
The reference standards: F-GSK1482160 ((S)-N-(3-
fluoro-4-(trifluoromethyl)benzyl)-1-methyl-5-
oxopyrrolidine-2-carboxamide), Br-GSK1482160 ((S)-
N-(3-bromo-4-(trifluoromethyl)benzyl)-1-methyl-5-
oxopyrrolidine-2-carboxamide),  I-GSK1482160 ((S)-N-
(3-iodo-4-(trifluoromethyl)benzyl)-1-methyl-5-
oxopyrrolidine-2-carboxamide); and their corresponding 
precursor: desmethyl-F-GSK1482160 ((S)-N-(3-fluoro-
4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide), desmethyl-Br-GSK1482160 ((S)-N-(3-
bromo-4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide),  desmethyl-I-GSK1482160 ((S)-N-(3-
iodo-4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide); were synthesized as outlined in Scheme 
1, according to the published methods.
7
 The starting 
materials were either commercially available or 
synthesized in our previous work.
7
 (S)-1-Methyl-5-
oxopyrrolidine-2-carboxylic acid underwent a coupling 
reaction with 2-halo-3-(trifluoromethyl)benzylamine (F-
, Br-, and I-) using 2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline (EEDQ) as a catalyst, affording halo-
GSK1482160 (F-, Br-, and I-). Likewise, (S)-5-
oxopyrrolidine-2-carboxylic acid underwent a coupling 
reaction with 2-halo-3-(trifluoromethyl)benzylamine (F-
, Br-, and I-) using EEDQ as a catalyst, giving 
desmethyl-halo-GSK1482160 (F-, Br-, and I-). The 
yields of the coupling reaction were in the range of 45-
93%. F-GSK1482160 appeared in the GlaxoSmithKline 
patents without biological activity data,
16,17
 Br-
GSK1482160, I-GSK1482160, and all three 
desmethylated precursors are new compounds. 
 
Synthesis of the target tracers [
11
C]F-GSK1482160 ((S)-
N-(3-fluoro-4-(trifluoromethyl)benzyl)-1-[
11
C]methyl-
5-oxopyrrolidine-2-carboxamide), [
11
C]Br-
GSK1482160 ((S)-N-(3-bromo-4-
(trifluoromethyl)benzyl)-1-[
11
C]methyl-5-
oxopyrrolidine-2-carboxamide),  and [
11
C]I-
GSK1482160 ((S)-N-(3-iodo-4-
(trifluoromethyl)benzyl)-1-[
11
C]methyl-5-
oxopyrrolidine-2-carboxamide) is presented in Scheme 
2. Desmethyl-halo-GSK1482160 (F-, Br-, and I-) 
underwent N-[
11
C]methylation
7 
using the reactive 
[
11
C]methylating agent [
11
C]methyl triflate 
([
11
C]CH3OTf)
18,19 
in acetonitrile at 80 °C under basic 
conditions (NaOH-Na2CO3, solid, w/w 1:2). The 
product was isolated by semi-preparative reverse-phase 
(RP) high performance liquid chromatography (HPLC) 
with a C-18 column,
 
and then concentrated by solid-
phase extraction (SPE) with a disposable C-18 Plus 
Sep-Pak cartridge to produce the corresponding pure 
radiolabeled compound [
11
C]halo-GSK1482160 (F-, Br-
, and I-) in 40-50%  radiochemical yield, decay 
corrected to end of bombardment (EOB), based on 
[
11
C]CO2. 
     
Desmethyl-halo-GSK1482160 (F-, Br-, and I-) contain 
both cyclic amide and side chain amide that can be N-
[
11
C]methylated. They are two competing reactions. 
Although the cyclic amide is more easily deprotonated 
and methylated than side chain amide to produce 
desired [
11
C]halo-GSK1482160 (F-, Br-, and I-), there 
  
 
was always a radiolabeled [
11
C]halo-GSK1482160 
isomer (F-, Br-, and I-) by-product [
11
C]-methylated at 
side chain amide position formed. During the 
development, validation and production of 
[
11
C]GSK1482160,
7
 We surprisingly found out 
[
11
C]GSK1482160 and its radiolabeled isomer were 
formed in different ratio using the old NaH base or 
freshly purchased NaH base. For old NaH used in 
development and optimization runs, [
11
C]GSK1482160 
was formed as a major labeled product; but for freshly 
purchased NaH (expired in one year) used in validation 
and production runs, undesired [
11
C]GSK1482160 
isomer was formed as a major labeled product. The 
reason could be that old NaH might have absorbed 
moisture to become NaOH and/or reacted with CO2 in 
the air to become NaHCO3, a solid mixture of NaOH-
Na2CO3. It is likely the different pKa value of cyclic 
amide and side chain amide requires different base for 
N-[
11
C]methylation. Consequently we investigated the 
base effect on the radiosynthesis of [
11
C]GSK1482160 
and its halo-analogs. The results are shown in Scheme 
3. If NaOH-Na2CO3 (w/w 1:2, solid) was used as a base, 
[
11
C]halo-GSK1482160 (F-, Br-, and I-) and [
11
C]halo-
GSK1482160 isomer (F-, Br-, and I-) were formed in a 
~10:1 ratio. If NaOH (solid) was used as a base, 
[
11
C]halo-GSK1482160 (F-, Br-, and I-) and [
11
C]halo-
GSK1482160 isomer (F-, Br-, and I-) were formed in a 
~1:1 ratio. If NaH (95% dry or 60% dispersion in 
mineral oil, powder) was used as a base, [
11
C]halo-
GSK1482160 (F-, Br-, and I-) and [
11
C]halo-
GSK1482160 isomer (F-, Br-, and I-) were formed in a 
~1:10 ratio. 
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [
11
C]-radiosynthesis 
module.
20-22
 Our radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. The 
radiosynthesis includes three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. The overall 
synthesis time was ~40 min from EOB. Our module is 
also designed to allow in-process measurement of [
11
C]-
tracer molar activity (AM, GBq/mol at EOB) using a 
radiation detector with a UV detector at the outlet of the 
HPLC-portion of the system. At the end of synthesis 
(EOS), the AM of [
11
C]-tracer was determined again by 
analytical RP-HPLC, calculated, decay corrected to 
EOB, and based on [
11
C]CO2, which was in agreement 
with the ‘on line’ determined value. The AM of 
[
11
C]halo-GSK1482160 analogs at EOB was 370-740 
GBq/mol.     
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.
23
 The chemical purity 
of the precursor and reference standard was >95% 
determined by RP-HPLC through UV flow detector. 
The radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through -ray (PIN diode) 
flow detector. 
  
 
Scheme 1. Synthesis of the reference standards halo-GSK1482160 (F-, 
Br-, and I-) and their corresponding precursor desmethyl-halo-
GSK1482160 (F-, Br-, and I-).    
 
 
Scheme 2. Synthesis of the target tracers [11C]halo-GSK1482160 (F-, Br-, 
and I-). 
 
The preliminary biological evaluation of halo-
GSK1482160 (F-, Br-, and I-) in comparison with the 
known P2X7R ligand GSK1482160 was performed by a 
  
 
radioligand competitive binding assay using 
[
11
C]GSK1482160 following the literature method.
8,12,13, 
24-26
 The results are shown in Figure 2. 
[
11
C]GSK1482160 was used as the radioligand, 
GSK1482160 and buffer were used as a positive control 
and a negative control, respectively. All data were 
analyzed by GraphPad Prism 7.00 software using 
nonlinear regression and the competitive binding model 
One site – Fit Ki. The binding affinity Ki values for 
GSK1482160 (F-, Br-, and I-) and GSK1482160 are 
54.2 ± 6.2 nM, 2.5 ± 0.7 nM, 1.9 ± 0.6 nM, and 3.1 ± 
0.3 nM (n =3), respectively. The IC50 values for 
GSK1482160 (F-, Br-, and I-) and GSK1482160 are 
152.6 ± 17.5 nM, 7.1 ± 1.9 nM, 5.3 ± 1.5 nM, and 8.9 ± 
1.0 nM (n =3), respectively, also obtained via GraphPad 
Prism 7.00 software using nonlinear regression and the 
competitive binding model One site – Fit logIC50.    
 
 
Scheme 3. Base effect on the radiosynthesis of [11C]GSK1482160 and its 
halo-analogs. 
 
 
Figure 2. The result of the competitive binding assay of halo-
GSK1482160 (F-, Br-, and I-) in comparison with GSK1482160. 
 
The experimental details and characterization data for 
halo-GSK1482160 (F-, Br-, and I-), desmethyl-halo-
GSK1482160 (F-, Br-, and I-), and [
11
C]halo-
GSK1482160 (F-, Br-, and I-), as well as radioligand 
competitive binding assay are given.
27 
 
 
In summary, facile synthetic routes with moderate to 
excellent yields have been developed to produce the 
precursors desmethyl-halo-GSK1482160 (F-, Br-, and I-
), the reference standards halo-GSK1482160 (F-, Br-, 
and I-), and the target PET radiotracers [
11
C]halo-
GSK1482160 (F-, Br-, and I-). The radiosynthesis 
employed [
11
C]CH3OTf for N-[
11
C]methylation at the 
nitrogen position of the amide precursors, followed by 
product purification and isolation by a semi-preparative 
RP-HPLC combined with SPE. The base effect on the 
radiotracer production of [
11
C]GSK1482160 and 
[
11
C]halo-GSK1482160 (F-, Br-, and I-) has been 
investigated. The desired [
11
C]halo-GSK1482160 (F-, 
Br-, and I-) were obtained in high radiochemical yield, 
and radiochemical purity, with a reasonably short 
overall synthesis time, and high molar activity. New 
P2X7R radioligands [
11
C]halo-GSK1482160 (F-, Br-, 
and I-) have been successfully radiosynthesized. The 
initial in vitro biological evaluation results indicate that 
[
11
C]F-GSK1482160 has ~17-fold less potency 
compared to the parent radioligand [
11
C]GSK1482160, 
but remains low nM grade P2X7R affinity; [
11
C]Br-
GSK1482160 and [
11
C]I-GSK1482160 display very 
similar even superior P2X7R affinity to 
[
11
C]GSK1482160. These will facilitate studies to 
evaluate [
11
C]Br-GSK1482160 and [
11
C]I-GSK1482160 
as new PET radiopharmaceuticals for targeting the P2X7 
receptor in animals and humans. The in vivo biological 
evaluation of [
11
C]Br-GSK1482160 and [
11
C]I-
GSK1482160 is currently underway. 
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chromatography (TLC) was run using Analtech silica 
gel GF uniplates (5  10 cm2).  Plates were visualized 
under UV light. Normal phase flash column 
chromatography was carried out on EM Science silica 
gel 60 (230-400 mesh) with a forced flow of the 
indicated solvent system in the proportions described 
below. All moisture- and air-sensitive reactions were 
performed under a positive pressure of nitrogen 
maintained by a direct line from a nitrogen source. 
C18 Plus Sep-Pak cartridges were obtained from 
Waters Corporation (Milford, MA).  Sterile Millex-FG 
0.2 m filter units were obtained from Millipore 
Corporation (Bedford, MA). [
11
C]GSK1482160 is a 
routine radiotracer produced in our PET 
radiochemistry facility. The analytical RP-HPLC 
system included a Prodigy (Phenomenex) 5 m C-18 
column, 4.6  250 mm, mobile phase 35% 
CH3CN/65% 20 mM H3PO4, flow rate 1.8 mL/min; 
UV (275 nm) and -ray (PIN diode) flow detectors. 
The semi-preparative RP-HPLC system included a 
Prodigy (Phenomenex) 5 m C-18 column, 10  250 
mm, mobile phase 35% CH3CN/65% 0.1 M 
CH3CO2Na, flow rate 6, 7, and 8 mL/min for [
11
C]F-
GSK1482160, [
11
C]Br-GSK1482160, and [
11
C]I-
GSK1482160, respectively; UV (254 nm) and -ray 
(PIN diode) flow detectors.        
(b). General synthetic method for F-GSK1482160 
((S)-N-(3-fluoro-4-(trifluoromethyl)benzyl)-1-methyl-
5-oxopyrrolidine-2-carboxamide), Br-GSK1482160 
((S)-N-(3-bromo-4-(trifluoromethyl)benzyl)-1-methyl-
5-oxopyrrolidine-2-carboxamide),  I-GSK1482160 
((S)-N-(3-iodo-4-(trifluoromethyl)benzyl)-1-methyl-5-
oxopyrrolidine-2-carboxamide); desmethyl-F-
GSK1482160 ((S)-N-(3-fluoro-4-
(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide), desmethyl-Br-GSK1482160 ((S)-N-(3-
bromo-4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide),  desmethyl-I-GSK1482160 ((S)-N-(3-
iodo-4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-
carboxamide): (S)-1-Methyl-5-oxopyrrolidine-2-
carboxylic acid or (S)-5-oxopyrrolidine-2-carboxylic 
acid (2.0 mmol) was suspended in CH2Cl2 (60 mL), 
and EEDQ (2.2 mmol) was added. The mixture was 
stirred at room temperature (RT) for 10 min. A 
solution of 2-fluoro-3-(trifluoromethyl)benzylamine 
(2.1 mmol), 2-bromo-3-(trifluoromethyl)benzylamine 
HCl salt (2.1 mmol) with N,N-Diisopropylethylamine 
(DIPEA, 3.0 mmol), or 2-iodo-3-
(trifluoromethyl)benzylamine (2.1 mmol) in CH2Cl2 
(20 mL) was then added dropwise to the mixture. The 
mixture was then stirred at RT for 15-16 h. The 
reaction was monitored by TLC. The mixture was 
washed with saturated aqueous NaHCO3 (40 mL), 2 N 
aqueous HCl (40 mL × 2), and water. The organic 
solution was dried over Na2SO4, filtered and 
concentrated in vacuo. The resulting crude product 
was then purified by column chromatography on silica 
gel with eluent (3-7% MeOH/CH2Cl2) to obtain white 
solid product (45-93%). F-GSK1482160: Mp 111-112 
C. 1H NMR (acetone-d6):  1.99-2.04 (m, 1H, CH), 
2.30-2.36 (m, 1H, CH), 2.37-2.47 (m, 2H, CH2), 2.78 
(s, 3H, NCH3), 4.01 (dd, J = 4.0, 4.9 Hz, 1H, CH), 
4.56 (d, J = 5.9 Hz, 2H, CH2), 6.82 (br s, 1H, NH), 
7.21 (t, J = 7.7 Hz, 1H, Ph-H), 7.57 (d, J = 7.6 Hz, 2H, 
Ph-H). MS (ESI): 319 ([M+H]
+
, 100%). Br-
GSK1482160: Mp 168-169 C. 1H NMR (CDCl3):  
2.03-2.05 (m, 1H, CH), 2.27-2.32 (m, 1H, CH), 2.36-
2.39 (m, 1H, CH), 2.42-2.47 (m, 1H, CH), 2.80 (s, 3H, 
NCH3), 4.00 (dd, J = 4.0, 4.5 Hz, 1H, CH), 4.62-4.66 
(m, 2H, CH2), 6.88 (br s, 1H, NH), 7.41 (t, J = 5.5 Hz, 
1H, Ph-H), 7.57 (d, J = 6.0 Hz, 1H, Ph-H), 7.64 (d, J = 
6.5 Hz, 1H, Ph-H). 
13
C NMR (CDCl3):  23.42, 29.22, 
29.42, 44.44, 63.81, 121.51, 122.81 (q, JC-F = 271.9 
Hz, CF3), 127.48 (q, JC-F = 5.4 Hz), 127.61, 131.21 (d, 
JC-F = 30.6 Hz), 133.86, 139.52, 171.50, 175.94. 
HRMS (ESI): calcd for C14H15N2O2BrF3 ([M+H]
+
) 
379.0264, found 379.0267. I-GSK1482160: Mp 175-
176 C. 1H NMR (CDCl3):  2.02-2.07 (m, 1H, CH), 
2.30-2.41 (m, 2H, CH2), 2.43-2.51 (m, 1H, CH), 2.83 
(s, 3H, NCH3), 4.01 (dd, J = 3.5, 5.0 Hz, 1H, CH), 
4.61-4.64 (m, 2H, CH2), 6.97 (br s, 1H, NH), 7.44 (t, J 
= 5.0 Hz, 1H, Ph-H), 7.55 (d, J = 7.5 Hz, 1H, Ph-H), 
7.61 (d, J = 7.5 Hz, 1H, Ph-H). 
13
C NMR (CDCl3):   
23.41, 29.30, 29.44, 49.56, 63.80, 96.63, 122.92 (q, JC-
F = 272.4 Hz, CF3), 127.22 (q, JC-F = 5.9 Hz), 128.49, 
132.98, 134.89 (d, JC-F = 30.5 Hz), 142.95, 171.40, 
175.87. HRMS (ESI): calcd for C14H15N2O2IF3 
([M+H]
+
) 427.0125, found 427.0125. Desmethyl-F-
GSK1482160: Mp 109-110 C. 1H NMR (acetone-d6): 
 2.12-2.17 (m, 1H, CH), 2.22-2.34 (m, 2H, CH2), 
2.45-2.53 (m, 1H, CH), 4.19 (dd, J = 4.5, 5.9 Hz, 1H, 
CH), 4.47-4.56 (m, 2H, CH2), 7.19 (br s, 1H, NH), 
  
 
7.21 (dd, J = 3.8, 5.6 Hz, 2H, Ph-H), 7.51 (t, J = 6.9 
Hz, 1H, Ph-H), 7.56 (br s, 1H, NH). 
13
C NMR 
(CDCl3):   25.66, 29.22, 36.95, 57.14, 118.40 (dd, JC-
F = 12.5, 32.5 Hz), 122.52 (q, JC-F = 271.2 Hz, CF3), 
124.13 (d, JC-F = 5.0 Hz), 126.45 (d, JC-F = 5.0 Hz), 
126.76 (d, JC-F = 137.5 Hz), 134.21 (d, JC-F = 3.7 Hz), 
157.84 (d, JC-F = 2.5 Hz), 172.66, 179.75. HRMS 
(ESI): calcd for C13H13N2O2F4 ([M+H]
+
) 305.0908, 
found 305.0911. Desmethyl-Br-GSK1482160: Mp 
190-191 C. 1H NMR (CDCl3):  2.02-2.05 (m, 1H, 
CH), 2.28-2.32 (m, 1H, CH), 2.36-2.40 (m, 1H, CH), 
2.42-2.47 (m, 1H, CH), 4.01 (dd, J = 4.0, 4.5 Hz, 1H, 
CH), 4.53-4.63 (m, 2H, CH2), 6.88 (br s, 1H, NH), 
7.41 (dd, J = 5.5, 7.0 Hz, 1H, Ph-H), 7.57 (d, J = 6.0 
Hz, 1H, Ph-H), 7.64 (d, J = 6.5 Hz, 1H, Ph-H), 7.69 
(br s, 1H, NH). 
13
C NMR (CDCl3 + CD3OD):  25.49, 
29.24, 43.95, 56.85, 121.10, 122.84 (q, JC-F = 272.5 
Hz, CF3), 127.02 (q, JC-F = 5.8 Hz), 127.35, 130.84 (d, 
JC-F = 30.8 Hz), 132.80, 139.41, 172.59, 179.69. 
HRMS (ESI): calcd for C13H13N2O2BrF3 ([M+H]
+
) 
365.0107, found 365.0111. Desmethyl-I-
GSK1482160: Mp 195-196 C. 1H NMR (acetone-d6): 
 2.13-2.19 (m, 2H, CH2), 2.20-2.32 (m, 1H, CH), 
2.44-2.51 (m, 1H, CH), 4.24 (dd, J = 3.0, 5.0 Hz, 1H, 
CH), 4.50-4.60 (m, 2H, CH2), 7.07 (br s, 1H, NH), 
7.54 (t, J = 7.5 Hz, 1H, Ph-H), 7.61 (d, J = 7.5 Hz, 1H, 
Ph-H), 7.64 (d, J = 7.5 Hz, 1H, Ph-H), 7.96 (br s, 1H, 
NH). 
13
C NMR (CDCl3 + CD3OD):  25.33, 29.16, 
49.30, 56.70, 95.89, 122.78 (q, JC-F = 272.1 Hz, CF3), 
126.63 (q, JC-F = 5.8 Hz), 128.09, 131.61, 134.40 (d, 
JC-F = 30.0 Hz), 142.58, 172.63, 179.66. HRMS (ESI): 
calcd for C13H13N2O2IF3 ([M+H]
+
) 412.9968, found 
412.9970. 
(c). General radiosynthetic method for [
11
C]F-
GSK1482160 ((S)-N-(3-fluoro-4-
(trifluoromethyl)benzyl)-1-[
11
C]methyl-5-
oxopyrrolidine-2-carboxamide), [
11
C]Br-GSK1482160 
((S)-N-(3-bromo-4-(trifluoromethyl)benzyl)-1-
[
11
C]methyl-5-oxopyrrolidine-2-carboxamide),  and 
[
11
C]I-GSK1482160 ((S)-N-(3-iodo-4-
(trifluoromethyl)benzyl)-1-[
11
C]methyl-5-
oxopyrrolidine-2-carboxamide): [
11
C]CO2 was 
produced by the 
14
N(p,)11C nuclear reaction in the 
small volume (9.5 cm
3
) aluminum gas target provided 
with the Siemens RDS-111 Eclipse cyclotron. The 
target gas consisted of 1% oxygen in nitrogen 
purchased as a specialty gas from Praxair, 
Indianapolis, IN. Typical irradiations used for the 
development were 55 A beam current and 30 min on 
target.  The production run produced approximately 
45.5 GBq of [
11
C]CO2 at EOB. In a small reaction vial 
(5 mL), the desmethylated precursor 4 (0.3-0.5 mg) 
was dissolved in CH3CN (500 L).  To this solution 
was added NaOH-Na2CO3 (solid, w/w 1:2, 1 mg). No 
carrier-added (high molar activity) [
11
C]CH3OTf that 
was produced by the gas-phase production method
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from [
11
C]CO2 through [
11
C]CH4 and [
11
C]CH3Br with 
silver triflate (AgOTf) column was passed into the 
reaction vial at RT, until radioactivity reached a 
maximum (~2 min), and then the reaction vial was 
isolated and heated at 80 

C for 3 min. The contents of 
the reaction vial were diluted with NaHCO3 solution 
(0.1 M, 1 mL), and injected onto the semi-preparative 
RP HPLC column with 3 mL injection loop for 
purification. The product fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Sep-
Pak Plus cartridge, and washed with water (5 mL × 4).  
The cartridge was eluted with EtOH (1 mL  2), 
followed by 10 mL saline, to release [
11
C]F-
GSK1482160, [
11
C]Br-GSK1482160, or [
11
C]I-
GSK1482160. The eluted product was then sterile-
filtered through a sterile vented Millex-FG 0.2 m 
filter, and collected into a sterile vial. Total 
radioactivity (4.6-8.2 GBq) was assayed and total 
volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis, purification and 
formulation time was ~40 min from EOB.  Retention 
times in the analytical RP-HPLC system were: tR 
desmethyl-F-GSK1482160 = 4.38 min, tR F-
GSK1482160 = 5.55 min, tR [
11
C]F-GSK1482160 = 
5.61 min; tR desmethyl-Br-GSK1482160 = 5.75 min, 
tR Br-GSK1482160 = 7.45 min, tR [
11
C]Br-
GSK1482160 = 7.52 min; and tR desmethyl-I-
GSK1482160 = 6.50 min, tR I-GSK1482160 = 8.55 
min, tR [
11
C]I-GSK1482160 = 8.63 min. Retention 
times in the semi-preparative RP-HPLC system were: 
tR desmethyl-F-GSK1482160 = 7.25 min, tR F-
GSK1482160 = 9.00 min, tR [
11
C]F-GSK1482160 = 
9.08 min; tR desmethyl-Br-GSK1482160 = 9.21 min, 
tR Br-GSK1482160 = 12.76 min, tR [
11
C]Br-
GSK1482160 = 12.82 min; and tR desmethyl-I-
GSK1482160 = 9.17 min, tR I-GSK1482160 = 12.80 
min, tR [
11
C]I-GSK1482160 = 12.93 min. The 
radiochemical yield was 40-50% decay corrected to 
EOB, based on [
11
C]CO2. 
(d). Cell culture and membrane preparation: HEK293 
cells expressing human recombinant P2X7 receptor 
(hP2X7R) were obtained from B’SYS GmbH and 
cultured according to the supplier’s procedure. Cells 
were grown to 80% confluency and then rinsed with 
phosphate-buffered saline (PBS), detached with 
trypsin, and harvested. Cell pellets were obtained by 
centrifugation at 200 g for 5 min at 4 °C. Collected 
cell pellets were frozen at −80 °C until membrane 
preparation. For the membrane preparation, pellets 
from 10 T225 flasks were homogenized in 50 mM 
Tris-HCl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), and 140 mM NaCl at pH 7.4 and 4 °C. The 
homogenate was then centrifuged at 48,000 g for 20 
min at 4 °C, gently rinsed with deionized water, and 
then resuspended in 50 mM Tris-HCl at pH 7.4 and 4 
°C. This homogenate was then centrifuged as before, 
with the resulting pellet being homogenized in 50 mM 
Tris-HCl at pH 7.4. Total protein concentration was 
determined via the Bradford protein assay (Bio-Rad). 
  
 
Aliquots were stored in cryovials at −80 °C until the 
day of assay. 
(e). [
11
C]GSK1482160 standards: For each 
experiment, the highest concentration of radioactivity 
used was diluted twice in assay buffer, followed by 
eleven 2-fold dilutions. Twenty microliters of each 
dilution were then spotted onto a GF/B UniFilter-96 
plate (Perkin-Elmer) and allowed to air-dry until the 
end of the experiment. An additional 20 L of each 
dilution were added to a scintillation vial containing 7 
mL of Optiphase Hisafe 3 (Perkin-Elmer) and counted 
on an LS6000 scintillation counter (Beckman). 
Aliquots of the working concentrations of 
radioactivity used on each day were counted in the 
same manner. 
(f). Radioligand competitive binding assay: For 
competitive binding assays, cell membrane 
preparation (0.054 mg of protein/mL of assay 
medium) was incubated with 11 compound 
concentrations over a six log unit range, with 5 
nM [
11
C]GSK1482160 in assay buffer (50 mM Tris-
HCl, pH 7.4, 0.1% bovine serum albumen (BSA)) .  
Triplicate determinations were done at each 
concentration of test compound. GSK1482160 was 
used to determine non-specific binding. Assays were 
incubated at 22 °C for 30 min.  For termination of the 
binding reaction, the samples were filtered onto GF/B 
UniFilter plates that had been presoaked in 0.5% 
polyethyleneimine for 30 min using a UniFilter-96 cell 
harvester. The plates were washed 5 times with ice-
cold saline, dried under a vacuum, and exposed to a 
TR2025 phosphor screen for 20–60 min. Phosphor 
screens were then read on a Typhoon FLA-7000IP 
(GE Healthcare) along with [
11
C]-calibration 
standards. CPMs (counts per minute) were determined 
by calibrating the image to the CPMs in the calibration 
standards via MCID analysis Software. Data was 
analyzed with Prism 7.00 (GraphPad Software Inc., La 
Jolla, California, USA) to determine Ki and IC50 
values. 
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